Bovidip 2% w/v Concentrate for Dip or Spray Solution

Main information

  • Trade name:
  • Bovidip 2% w/v Concentrate for Dip or Spray Solution
  • Pharmaceutical form:
  • Teat dip concentrate
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Bovidip 2% w/v Concentrate for Dip or Spray Solution
    Netherlands
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • Tars
  • Therapeutic area:
  • Cattle Females

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • UK/V/0331/001
  • Authorization date:
  • 07-01-2011
  • EU code:
  • UK/V/0331/001
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

Revised:November2012

AN.01679/2011

Page1of5

SUMMARYOFPRODUCTCHARACTERISTICS

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

Bovidip2%w/vConcentrateforTeatDiporSpraySolution

forcows.

2 QUALITATIVEANDQUANTITATIVECOMPOSITION

Activesubstance:iodine,2%w/v

2gper100mlasavailableiodine(concentrate).

25mgper5mldoseasavailableiodine(ready-to-use

solution).

Excipients

Emollients: glycerol,10%w/v

Forafulllistofexcipients,seesection6.1

3. PHARMACEUTICALFORM

ConcentrateforTeatDiporSpraySolution.

ClearBrownLiquid.

4. CLINICALPARTICULARS

4.1 Targetspecies

Bovine.

4.2 Indicationsforuse,specifyingthetargetspecies

Teatdisinfectionasanaidinthepreventionofmastitisinlactatingdairycows.

4.3 Contra-indications

Donotuseincasesofknownhypersensitivitytoiodine,ortoanyofthe

excipients.

Donotmixwithotherchemicals.

4.4 Specialwarningsforeachtargetspecies

Priortomilking,washteatswithanudderwashsolutionanddrywitha

disposablepapertowel.

Discardanyproductthatbecomescontaminated.

Revised:November2012

AN.01679/2011

Page2of5

4.5 Specialprecautionsforuse

i)Specialprecautionsforuseinanimals

Allowproducttodrybeforeexposingthecowstowet(rainy),coldorwindy

conditions.

Useininjuredteatsmaydelaythewound-healingprocess.Itis

recommendedthattreatmentbediscontinueduntilteatlesionshave

resolved.

Ifsignsofdiseasepersistorappear,consultaveterinarysurgeon.

ii)Specialprecautionsforthepersonadministeringtheveterinarymedicinal

producttoanimals

Careshouldbetakenavoideyecontact.Incaseofeyecontact,flushthe

eyeswithcopiousamountsofwaterandseekmedicaladvice.

Incaseofingestion,drinklargequantitiesofwaterandobtainmedical

attentionassoonaspossible.

Whenusedasspray,avoidworkinginspraymist.

Washhandsafteruse.

Personswithiodineallergyshouldwearglovesandmask.

iii)Otherprecautions

None.

4.6 Adversereactions

Noneknown.

4.7. Useduringpregnancy,lactationorlay

Indicatedforuseduringpregnancyandlactation.

4.8.Interactionwithothermedicinalproductsandotherformsofinteraction

Theuseofthisproductinthespecifiedmanner(topicalantiseptic)hasno

knowninteractionswithothermedicamentsornutrition.

4.9.Amountstobeadministeredandadministrationroute

Dilutebeforeuse.Prepareafreshsolutiondaily.DiluteonepartofBovidip2%

w/vConcentrateforTeatDiporSpraySolutionwiththreepartsofcleanwater

andmixwell.Alwayscleanthedipcuporspraycontainerafteruse.

Amountstobeadministered:about5mlpercowperapplication.

Administrationroute:

oDipping:Dipeachteatimmediatelyaftermilkinginateatdipcup

containingdilutedproduct.Dipthefulllengthoftheteatsandreplenish

thedipcupasnecessary.

oSpraying:Spraytheentiresurfaceoftheteatsaftereachmilking.

Revised:November2012

AN.01679/2011

Page3of5

4.10.Overdose

Notapplicable.Theproductisfortopicalapplication.Significantabsorption

doesnotoccur.

4.11.Withdrawalperiods

Meat:Zerodays.

Milk:Zerohours.

5. PHARMACOLOGICALPROPERTIES

PharmacotherapeuticGroup:Productsforteatsandudders:Disinfectants

ATCVetCode:QG52A

5.1.Pharmacodynamicproperties

Iodinesolutionsreactwiththeorganicmatterofbacteriaandvirusestorender

themharmless.Themechanismofkillappearstobeduetoanoxidative-

reductivereaction,involvingvariouscellwallconstituents,whichare

irreversiblytransformed.Thesulphydryllinkages,inbacterialcellwall

components,arespecificallytargetedbyiodine.

Bovidip2%w/vConcentrateforTeatDiporSpraySolutionisbactericidal(EN

1040andEN1656)against:

Pseudomonasaeruginosa

Staphylococcusaureus

Enterococcushirae

Proteusvulgaris

5.2. Pharmacokineticparticulars

Literaturesuggeststhatabsorptionofiodinethroughtheskiniswellbelow

levelswhichwouldleadtopharmacokineticactivityinthebody.

6. PHARMACEUTICALPARTICULARS

6.1. Listofexcipients

WaterPurified

Glycerol

Macrogollaurylether

Poloxamer

Sodiumiodide

Citricacidmonohydrate

Sodiumhydroxide

Revised:November2012

AN.01679/2011

Page4of5

6.2.Incompatibilities

Intheabsenceofcompatibilitystudies,thisveterinarymedicinalproductmust

notbemixedwithotherveterinarymedicinalproducts.

6.3.Shelflife

Shelflifeoftheveterinarymedicinalproductaspackagedforsale:18months.

Shelflifeafterfirstopeningtheimmediatepackaging:6months.

Shelflifeafterdilutionaccordingtodirections:1day.

6.4.Specialprecautionsforstorage

Storeuprightinthetightlyclosedoriginalcontainer.

Donotstoreabove25°C.

Protectfromfrost.

Iftheproducthasfrozen,thawinawarmplaceandshakewellbeforeuse.For

thelargerpacksizes,theproductshouldberolledsufficientlytomixthe

solution.Undernocircumstancesshouldanattemptbemadetoshakethe60

or200litrepacks.

Protectfromlight.

6.5.Natureandcompositionofimmediatepackaging

High-densitypolyethylene5,10,20,60or200litrecansclosedwithhigh-

densitypolyethylenescrewcaps,securedwithasealingring.

The200litrecontainershouldnotbereturnedforre-filling.

Notallpacksizesmaybemarketed.

6.6.Specialprecautionsforthedisposalofunusedveterinarymedicinal

productsorwastematerialsderivedfromtheuseofsuchproducts,if

appropriate

Anyunusedveterinarymedicinalproductorwastematerialsderivedfromsuch

veterinarymedicinalproductsshouldbedisposedofinaccordancewithlocal

requirements.

7. MARKETINGAUTHORISATIONHOLDER

DeLavalInternationalAb

Industriepark-Drongen10

B-9031Gent

Belgium

8. MARKETINGAUTHORISATIONNUMBERS

UK: Vm17140/4008

Ireland: 10827/003/001

Revised:November2012

AN.01679/2011

Page5of5

9. DATEOFTHEFIRSTAUTHORISATION

09July2007

10. DATEOFREVISIONOFTHETEXT

November2012

14-12-2018

Analysis of hunting statistics collection frameworks for wild boar across Europe and proposals for improving the harmonisation of data collection

Analysis of hunting statistics collection frameworks for wild boar across Europe and proposals for improving the harmonisation of data collection

Published on: Thu, 13 Dec 2018 Heterogeneities in the wild boar data collection frameworks across Europe were analysed using questionnaires to explore comparability of hunting data in the short term and propose a common framework for future collection. Fifty‐seven respondents representing 32 countries covering more than 95% of European territory participated to the questionnaire. The most frequently recorded information in the official statistics included the quantity of animals shot per hunting ground ...

Europe - EFSA - European Food Safety Authority Publications

13-12-2018

Evaluation of the safety and efficacy of the organic acids lactic and acetic acids to reduce microbiological surface contamination on pork carcasses and pork cuts

Evaluation of the safety and efficacy of the organic acids lactic and acetic acids to reduce microbiological surface contamination on pork carcasses and pork cuts

Published on: Wed, 12 Dec 2018 Studies evaluating the safety and efficacy of lactic and acetic acids to reduce microbiological surface contamination on pork carcasses pre‐chill and pork meat cuts post‐chill were assessed. Lactic acid treatments consisted of 2–5% solutions at temperatures of up to 80°C applied to carcasses by spraying or up to 55°C applied on cuts by spraying or dipping. Acetic acid treatments consisted of 2–4% solutions at temperatures of up to 40°C applied on carcasses by spraying or o...

Europe - EFSA - European Food Safety Authority Publications

5-7-2018

Scientific guideline:  Draft pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml product-specific bioequivalence guidance, draft: consultation open

Scientific guideline: Draft pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml product-specific bioequivalence guidance, draft: consultation open

This document provides product-specific guidance on the demonstration of the bioequivalence of pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml.

Europe - EMA - European Medicines Agency